SciSparc Ltd. (NASDAQ: SPRC) continued its ascent in the post-market trading session on Friday, witnessing a notable surge. The valuation of SciSparc stock experienced a robust 5.86% upswing, reaching $10.65 during the extended trading hours. This momentum seamlessly extended from the regular trading session, where SPRC stock exhibited an impressive surge of 35.22%, ultimately concluding at $10.06. The surge in SPRC stock was catalyzed by the commencement of a clinical trial.
SciSparc (SPRC) has commenced a clinical trial featuring its exclusive therapeutic solution, SCI-210. Groundbreaking research is presently in progress at Soroka Medical Center in Israel, concentrating on alleviating symptoms linked to Autism Spectrum Disorder (ASD) in youngsters.
The 20-week experiment aims to enlist 60 participants aged 5 to 18. Scientific evaluations will methodically assess the effectiveness of SCI-210 compared to conventional CBD therapy in handling ASD symptoms. The trial adheres strictly to the highest standard of clinical research, utilizing a randomized, double-blind, placebo-controlled framework.
This pioneering intervention not only aims to improve autism symptoms but also tackles the prevalent side effects connected to cannabis-derived treatments, including CBD. Through collaborative efforts with Soroka Medical Center and the National Autism Research Center, SciSparc is pioneering new avenues in ASD treatment. The commitment is rooted in scientific advancements, with a primary objective of enhancing the quality of life for children with ASD and their families.
The spectrum of ASD poses diverse challenges, impacting social interaction and communication skills. SciSparc’s ambitious initiative aims to illuminate a more promising and interconnected future for individuals within the autism spectrum.
Additionally, in a strategic move last week, SciSparc formalized a non-binding letter of intent for a merger with a prominent vehicle importing company in Israel (referred to as the “Target Company”). The merger is anticipated to materialize through a reverse triangular merger structure. According to the agreement, SciSparc will establish a new wholly-owned Israeli subsidiary, which will subsequently merge with and into the Target Company, resulting in the Target Company as the surviving entity.
